Jane Street’s Black Diamond Therapeutics BDTX Stock Holding History

Jane Street’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$536K	Buy	289,712 +194,881	+206%	+$477K	﹤0.01%	7854
2026 Q1	$202K	Sell	94,831 -866,945	-90%	-$2.06M	﹤0.01%	10127
2025 Q4	$2.34M	Buy	961,776 +724,503	+305%	+$2.57M	﹤0.01%	4502
2025 Q3	$899K	Buy	237,273 +28,796	+14%	+$84.2K	﹤0.01%	6546
2025 Q2	$517K	Buy	+208,477	New	+$402K	﹤0.01%	6861
2024 Q4	–	Sell	-26,025	Closed	-$113K	–	9386
2024 Q3	$113K	Buy	+26,025	New	+$142K	﹤0.01%	8946
2024 Q2	–	Sell	-250,555	Closed	-$1.27M	–	9356
2024 Q1	$1.27M	Buy	250,555 +195,285	+353%	+$787K	﹤0.01%	4969
2023 Q4	$155K	Buy	+55,270	New	+$130K	﹤0.01%	8378
2023 Q1	–	Sell	-12,914	Closed	-$23.2K	–	9024
2022 Q4	$23.2K	Buy	+12,914	New	+$23.3K	﹤0.01%	8572
2022 Q1	–	Sell	-37,866	Closed	-$202K	–	10278
2021 Q4	$202K	Buy	+37,866	New	+$265K	﹤0.01%	8806
2021 Q3	–	Sell	-18,523	Closed	-$226K	–	9920
2021 Q2	$226K	Buy	18,523 +6,902	+59%	+$136K	﹤0.01%	8633
2021 Q1	$282K	Sell	11,621 -6,999	-38%	-$189K	﹤0.01%	7787
2020 Q4	$597K	Buy	+18,620	New	+$612K	﹤0.01%	5468

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Jane Street's BDTX Position: Q2 2026 in Review

Jane Street increased its Black Diamond Therapeutics (BDTX) stake by 206% in Q2 2026, buying an estimated $477K and bringing the position to 289,712 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #7854.

Jane Street first reported a position in BDTX in Q4 2020 and has held it in 13 quarters since. The position peaked at $2.34M in Q4 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Jane Street held 289,712 shares of Black Diamond Therapeutics worth $536K as of Q2 2026.
Jane Street bought 194,881 Black Diamond Therapeutics shares in Q2 2026, an estimated $477K.
Black Diamond Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7854 holding.
Jane Street first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 13 quarters since.
Jane Street's Black Diamond Therapeutics position peaked at $2.34M in Q4 2025.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.